Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.44 |
| ▸ | ACE | P12821 | 2/20 | 0.44 |
| ▸ | CPA1 | P15085 | 2/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.32 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.32 |
| ▸ | ENPEP | Q07075 | 6/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13851758 | 1.00 | MME (0.44) | MMEACECPA1ACE2ALDH1A1 | |
| SCHEMBL23784763 | 0.83 | ALDH1A1 (0.42) | MMEACECPA1ACE2ALDH1A1 | |
| SCHEMBL20342224 | 0.83 | ALDH1A1 (0.42) | MMEACECPA1ACE2ALDH1A1 | |
| SCHEMBL14397274 | 0.81 | MME (0.39) | MMEACECPA1ACE2ALDH1A1 | |
| SCHEMBL13851596 | 0.81 | ALDH1A1 (0.40) | MMEACECPA1ACE2ALDH1A1 | |
| SCHEMBL15601940 | 0.80 | SLC22A6 (0.35) | SLC22A6ENPEPTDP1FFAR3 | |
| SCHEMBL16058580 | 0.79 | ADAMTS4 (0.41) | ALDH1A1SLC22A6CACNA2D1CACNB3CACNA1C | |
| SCHEMBL13108077 | 0.79 | ADAMTS4 (0.41) | ALDH1A1SLC22A6CACNA2D1CACNB3CACNA1C | |
| SCHEMBL17169644 | 0.79 | ADAMTS4 (0.41) | ALDH1A1SLC22A6CACNA2D1CACNB3CACNA1C | |
| Hydrochloric Acid SCHEMBL5419964 | 0.77 | ADAMTS4 (0.40) | ALDH1A1SLC22A6CACNA2D1CACNB3CACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8435941-B2 | Mini-hepcidin peptides and methods of using thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-05-07 | — | — | US | claimed |
| US-20210128690-A1 | METHODS OF ADMINISTERING HEPCIDIN | LA JOLLA PHARMACEUTICAL COMPANY | 2021-05-06 | — | — | US | disclosed |
| CN-110520147-A | For treating the composition and method of iron overload | LA JOLLA PHARMA CO | 2019-11-29 | — | — | CN | disclosed |
| US-20190336583-A1 | COMPOSITIONS AND METHODS FOR TREATING IRON OVERLOAD | LA JOLLA PHARMACEUTICAL COMPANY | 2019-11-07 | — | — | US | disclosed |
| EP-3558343-A1 | METHODS OF ADMINISTERING HEPCIDIN | La Jolla Pharmaceutical Company (US) | 2019-10-30 | — | — | EP | disclosed |
| CN-110312521-A | Method of administering hepcidin | 拉卓拉药物公司 | 2019-10-08 | — | — | CN | disclosed |
| US-20190240292-A1 | METHODS OF ADMINISTERING HEPCIDIN | LA JOLLA PHARMACEUTICAL COMPANY | 2019-08-08 | — | — | US | disclosed |
| CN-108883154-A | The method for applying hepcidin | 拉卓拉药物公司 | 2018-11-23 | — | — | CN | disclosed |
| EP-3399996-A1 | METHODS OF ADMINISTERING HEPCIDIN | La Jolla Pharmaceutical Company (US) | 2018-11-14 | — | — | EP | disclosed |
| WO-2018175633-A1 | METHODS OF INDUCING ANTI-MALARIAL IMMUNE RESPONSES AND COMPOSITIONS RELATED THERETO | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2018-09-27 | — | — | WO | disclosed |
| WO-2018136636-A1 | COMPOSITIONS AND METHODS FOR TREATING IRON OVERLOAD | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2018-07-26 | — | — | WO | disclosed |
| WO-2018118979-A1 | METHODS OF ADMINISTERING HEPCIDIN | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2018-06-28 | — | — | WO | disclosed |
| US-20180099023-A1 | METHODS OF TREATING IRON OVERLOAD | LA JOLLA PHARMACEUTICAL COMPANY | 2018-04-12 | — | — | US | disclosed |
| US-20170246256-A1 | METHODS OF ADMINISTERING HEPCIDIN | LA JOLLA PHARMACEUTICAL COMPANY | 2017-08-31 | — | — | US | disclosed |
| WO-2017120419-A1 | METHODS OF ADMINISTERING HEPCIDIN | LA JOLLA PHARMACEUTIAL COMPANY (US) | 2017-07-13 | — | — | WO | disclosed |
| US-20120071329-A1 | METHODS FOR IDENTIFYING COMPOUNDS OF INTEREST USING ENCODED LIBRARIES | GLAXOSMITHKLINE LLC (US) | 2012-03-22 | — | — | US | disclosed |
| US-20110251089-A1 | METHODS FOR SYNTHESIS OF ENCODED LIBRARIES | GLAXOSMITHKLINE (US) | 2011-10-13 | — | — | US | disclosed |
| US-7989395-B2 | Methods for identifying compounds of interest using encoded libraries | GLAXOSMITHKLINE LLC (US) | 2011-08-02 | — | — | US | disclosed |
| EP-2338990-A2 | Methods for synthesis of encoded libraries | Praecis Pharmaceuticals Inc. (US) | 2011-06-29 | — | — | EP | disclosed |
| US-20110136697-A1 | METHODS FOR SYNTHESIS OF ENCODED LIBRARIES | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099023-A1 | METHODS OF TREATING IRON OVERLOAD | HAMP, FTH1, SLC40A1 | MME 438/4885ACE 2745/4885CPA1 795/4885 |
| US-20210128690-A1 | METHODS OF ADMINISTERING HEPCIDIN | HAMP, FTH1, HDGF | MME 482/4885ACE 3188/4885CPA1 181/4885 |
| US-20170246256-A1 | METHODS OF ADMINISTERING HEPCIDIN | HAMP, FTH1, HDGF | MME 482/4885ACE 3188/4885CPA1 181/4885 |
| US-20110251089-A1 | METHODS FOR SYNTHESIS OF ENCODED LIBRARIES | RNGTT, DTYMK, DUT | MME 562/4885ACE 421/4885CPA1 1976/4885 |
| US-20190240292-A1 | METHODS OF ADMINISTERING HEPCIDIN | HAMP, FTH1, HDGF | MME 482/4885ACE 3188/4885CPA1 181/4885 |
| US-20190336583-A1 | COMPOSITIONS AND METHODS FOR TREATING IRON OVERLOAD | HAMP, FTH1, SLC40A1 | MME 693/4885ACE 3829/4885CPA1 1056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.